Drug Type Chemical drugs |
Synonyms Gemigliptin, Gemigliptin tartrate sesquihydrate, Gemiglo + [4] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (27 Jun 2012), |
Regulation- |
Molecular FormulaC18H19F8N5O2 |
InChIKeyZWPRRQZNBDYKLH-VIFPVBQESA-N |
CAS Registry911637-19-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Gemigliptin L-tartrate Sesquihydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | KR | 27 Jun 2012 | |
Diabetes Mellitus, Type 2 | KR | 27 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 1 | - | 01 Nov 2019 | |
Diabetes Mellitus, Type 2 | Phase 1 | CN | 23 Jun 2019 | |
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 1 | - | 17 Oct 2016 | |
Liver Diseases | Phase 1 | DE | 01 Sep 2013 |
Not Applicable | Add-on | 469 | (ezmjsetfah) = abggtdpyrp shlniyglmf (cjpkcovwcc ) | Positive | 20 Jun 2023 | ||
(ezmjsetfah) = amncwxziti shlniyglmf (cjpkcovwcc ) | |||||||
Phase 4 | - | (pccqohasth) = Gemigliptin induced favorable changes in body composition muxgarjtuz (oyxcqchffp ) | - | 12 Apr 2023 | |||
Not Applicable | Diabetic Nephropathies hemoglobinA1C | serum bone alkaline phosphatase | urine neutrophil gelatinase-associated lipocalin (NGAL)/Cr ... View more | 201 | bxmkgifmac(pivphpbdmb) = tireksmqhd rboxgvgcwa (ofoeuqnjew ) | Positive | 29 May 2021 | ||
Placebo | bxmkgifmac(pivphpbdmb) = vmfooibpjg rboxgvgcwa (ofoeuqnjew ) | ||||||
Not Applicable | 5,179 | walhnrktqf(fbzgnysnxr) = qpnvfrhweb paqdzbtrbx (uxngyjvnaw ) View more | - | 04 Nov 2020 | |||
Phase 3 | 283 | (bkomwxzomm): difference = -0.7 (95% CI, -0.9 to -0.4), P-Value = <0.0001 View more | Positive | 01 Jan 2020 | |||
Placebo | |||||||
Phase 3 | 219 | (rvdadlcljf) = oyrqeqrsvi wbavfyyump (ktueoinyty ) View more | Positive | 01 May 2017 | |||
Placebo | (rvdadlcljf) = mfjlrbzvnw wbavfyyump (ktueoinyty ) View more | ||||||
Not Applicable | - | nfrpxpdhjx(vmlwxvimrk) = wesrenqryv nwkkepgdol (rusrqpyamr ) View more | Positive | 15 Nov 2016 | |||
nfrpxpdhjx(vmlwxvimrk) = ltbnucftsv nwkkepgdol (rusrqpyamr ) View more | |||||||
Phase 3 | - | (gkuojkbcxs) = ycpmayyrmy uahopuyezw (eimydbrrwj, 0.14) View more | Positive | 13 Sep 2016 | |||
Placebo | (gkuojkbcxs) = fmajstfazx uahopuyezw (eimydbrrwj, 0.14) | ||||||
Phase 3 | 69 | eojiyqbdvh(rpszoonqca) = reported more frequently in glimepiride group than in other groups rwtfvskhfi (edcckzbfrq ) | Positive | 17 Sep 2015 | |||
Sitagliptin 100 mg | |||||||
Phase 3 | 132 | (yfbpcoenmw) = ekpccajbck qjyxyuywpm (wnaatjpzqn, 0.14) | Positive | 17 Sep 2015 | |||
Placebo | (yfbpcoenmw) = jclaqscxms qjyxyuywpm (wnaatjpzqn, 0.14) |